Topic 447: development and testing of a non-invasive cryo-device to prevent chemotherapy-induced peripheral neuropathy in hands and feet of cancer patients receiving taxol for breast cancer.
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91023C00036
- Awardee
-
Eisana Corp UEI LUW6W9WL7CX5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $399,824
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20231 · Posted Jul 20, 2022
- Contract value 88% obligated
-
- $399,824.00 Current, with exercised options
- $454,824.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 2 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- The Woodlands, TX 77382, USA
- Research
- STTR Phase I
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $399,824 |
About this award
This $454,824 Firm Fixed Price contract was awarded to Eisana Corp, a woman-owned small business, by the National Cancer Institute (NCI) to develop and test a non-invasive cryo-device to prevent chemotherapy-induced peripheral neuropathy in the hands and feet of cancer patients receiving Taxol for breast cancer. The contract was awarded under the Small Business Innovation Research (STTR) Phase I program and has a total small business set-aside. The contract supports the NCI's mission to conduct and support cancer research. The original solicitation sought innovative research proposals across multiple NIH and CDC topic areas to contribute to their respective missions and SBIR program objectives.
Quick answers
Who was awarded contract 75N91023C00036?
75N91023C00036 was awarded to Eisana Corp by National Cancer Institute (National Institutes of Health) on September 11, 2023.
How much is contract 75N91023C00036 worth?
The government has obligated $399,824 on 75N91023C00036. Its potential value, with all options, is $454,824.
Was contract 75N91023C00036 competed?
The extent of competition for 75N91023C00036 was full and open competition after exclusion of sources. The government received 2 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award